Secukinumab’s growing number of indications and its body of positive data may help it to compete for a substantial share of the inflammatory disease market against an increasing number of US- and EU-approved biosimilars, including 4 recently launched adalimumab biosimilars in the European Union.
This week, Novartis announced that the European Commission (EC) approved a label update for secukinumab, sold as Cosentyx. Secukinumab is a targeted biologic therapy for the treatment of psoriatic arthritis (PsA) that inhibits IL-17A, a cytokine involved in inflammation of entheses.
According to Novartis, the label update is significant, as PsA can lead to mobility loss and irreversible joint damage if not treated properly. PsA is a chronic, progressive disease that leads to pain and fatigue as well as activity impairment and significant mobility loss due to structural damage.
“Cosentyx has shown that it can slow the progression of joint damage inflicted by psoriatic arthritis, which can lead to significant mobility loss for patients,” said Paul Emery, professor of rheumatology at the University of Leeds in the United Kingdom.
The update includes dosing flexibility of up to 300 mg based on clinical response that will provide clinicians with dosing flexibility, as well as 24-week structural disease progression data with subcutaneous regimens demonstrating that secukinumab inhibits the progression of joint damage in PsA.
The trial, FUTURE 5, is the largest phase 3 study for a biologic conducted in PsA to date, with an enrollment of 996 patients. The study found that nearly 90% of patients treated with 300 mg of secukinumab had no radiographic disease progression at 24 weeks.
“Cosentyx is the only IL-17A inhibitor to demonstrate a 5-year safety and efficacy in phase 3 studies of PsA and [ankylosing spondylitis]. We are reimagining the well-being of patients living with all facets of psoriatic arthritis,” said Eric Hughes, Global Development Unit Head, Immunology, Hepatology, and Dermatology.
The updated label applies to all European Union and European Economic Area countries and takes effect immediately.
Secukinumab’s growing number of indications and its body of positive data may help it to compete for a substantial share of the inflammatory disease market against an increasing number of US- and EU-approved biosimilars, including 4 recently launched adalimumab biosimilars in the European Union.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.